Calix[n]arenes as goldmines for the development of chemical entities of pharmaceutical interest

Current Pharmaceutical Design

Volumn 19, Issue 36, 2013, Pages 6507-6521

  Varejão, Eduardo Vinícius Vieira ^a   de Fátima, Ângelo ^b   Fernandes, Sergio Antonio ^a  

^a FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Calix n arene; Drug delivery; Drug solubility; Host guest chemistry; Inclusion complex; Spectroscopic methods; Supramolecular chemistry

Indexed keywords

ANTIINFECTIVE AGENT; ARGININE; ASCORBIC ACID; ASPARTIC ACID; BOVINE SERUM ALBUMIN; CALIX[4]ARENE TETRABUTYLAMIDE; CALIX[N]ARENE DERIVATIVE; CARBAMAZEPINE; CHLORIN E6; DOXORUBICIN; FOLATE CALIX[4]ARENE; FUROSEMIDE; INDOMETACIN; ISONIAZID; LIPOPOLYSACCHARIDE; NALIDIXIC ACID; NICLOSAMIDE; NIFEDIPINE; NORFLOXACIN; ORNITHINE; P SULFONIC ACID CALIX[4]ARENE; P SULFONIC ACID CALIX[6]ARENE; P SULFONIC ACID CALIX[8]ARENE; POLY(ETHYLENE GLYCOL) CALIX[4]ARENE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROXYMETACAINE; SODIUM P SULFONATOCALIX[4]ARENE; TETRACAINE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALYTIC METHOD; ANTIBACTERIAL ACTIVITY; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CANCER CHEMOTHERAPY; CHEMICAL STRUCTURE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION COEFFICIENT; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG RELEASE; DRUG SOLUBILITY; ESCHERICHIA COLI; FLUORESCENCE SPECTROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; ISOTHERMAL TITRATION CALORIMETRY; LUNG CANCER; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR INTERACTION; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR OVERHAUSER EFFECT; OVARY CANCER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAMAN SPECTROMETRY; REVIEW; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS; STATIC ELECTRICITY; STOICHIOMETRY; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY; UTERINE CERVIX CANCER; X RAY CRYSTALLOGRAPHY; X RAY POWDER DIFFRACTION;

CALIXARENES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; METABOLIC DETOXICATION, DRUG; PHARMACEUTICAL PREPARATIONS;

EID: 84887857798     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990406     Document Type: Review

References (72)

1. Sansone F, Baldini L, Casnati, A, Ungaro R. Calixarenes: from biomimetic receptors to multivalent ligands for biomolecular recognition. New J Chem 2010; 34: 2715-28.
2. McGovern RE, Fernandes H, Khan AR, Power NP, Crowley PB. Protein camouflage in cytochrome c-calixarene complexes. Nature Chem 2012; 4: 527-33.
3. Muthiac L, Lee JH, Kim JS, Vicens J. Recognition of amino acids by funcionalized calixarenes. Chem Soc Rev 2011; 40: 2777-96.
4. da Silva DL, Fernandes SA, Sabino AA, de Fatima A. p-sulfonic acid calixarenes as efficient and reusable organocatalysts for the synthesis of 3, 4-dihydripyrimidin-2-(1H)-ones/-thiones. Tetrahedron Lett 2011; 52: 6328-30.
5. Fernandes SA, Natalino, R, Gazolla PAR, da Silva MJ, Jham GN. p-Sulfonic acid calix[n]arenes as homogeneous and recyclable or-ganocatalysts for esterification reactions. Tetrahedron Lett 2012; 53: 1630-3.
6. Santos LS, Fernandes SA, Pilli RA, Marsaioli AJ. A novel asymmetric reduction of dihydro-β-carboline derivatives using calix[6]arene/chiral amine as a host complex. Tetrahedron: Asymmetry 2003; 14: 2515-9.
7. 1H NMR spectroscopy. Catal Commun 2012; 26: 127-31.
8. Simões JB, da Silva DL, de Fátima A, Fernandes SA. Calix[n]arenes in action: useful host-guest catalysis in organic chemistry. Curr Org Chem 2012; 16: 949-71.
9. Kalchenko VI. Calixarene receptors for environmentally hazardous and biorelevant molecules and ions. Pure and Appl Chem 2008; 80: 1449-58.
10. Korbakov N, Timmerman P, Lidich N, Urbach B, Sa'ar A, Yitzchaik S. Acetylcholine detection at micromolar concentrations with the use of an artificial receptor-based fluorescence switch. Langmuir 2008; 24: 2580-7.
11. Jin T. Near-infrared fluorescence detection of acetylcholine in aqueous solution using a complex of rhodamine 800 and psulfonato-calix[8]arene. Sensors 2010; 10: 2438-49.
12. Nau, WM, Ghale G, Hennig A, Bakirci H, Bailey DM. Substrateselective supramolecular tandem assays: monitoring enzyme inhibition of arginase and diamine oxidase by fluorescent dye displacement from calixarene and cucurbituril macrocycles. J Am Chem Soc 2009; 131: 11558-70.
13. Guo D-S, Uzunova VD, Su X, Liu Y, Nau WM. Operational calixarene-based fluorescent sensing systems for choline and acetylcholine and their application to enzymatic reactions. Chem Sci 2011; 2: 1722-34.
14. Muthiac L. Calix[n]arenes as synthetic membrane transporters: A minireview. Anal Lett 2010; 43: 1355-66.
15. Mokhtari B, Pourabdollah K, Dalali N. Analytical applications of calixarenes from 2005 up-to-date. J Incl Phenom Macrocycl Chem 2011; 69: 1-55.
16. Rodik RV, Boyko VI, Kalchenko VI. Calixarenes in bio-medical researchers. Curr Med Chem 2009; 16: 1630-55.
17. de Fátima A, Fernandes SA, Sabino AA. Calixarenes as new platforms for drug design. Curr Drug Discov Technol 2009; 6: 151-70.
18. Sliwa W, Deska M. Functionalization reactions of calixarenes. Arkivoc 2011; 1: 496-551.
19. Guo D-S, Wang L-H, Liu Y. Highly effective binding of methyl viologen dication and its radical cation by psulfonatocalix[4, 5]arenes. J Org Chem 2007; 72: 7775-8.
20. Wang K, Guo DS, Zhang HQ, Li D, Zheng XL, Liu Y. Highly effective binding of viologens by p-sulfonatocalixarenes for the treatment of viologen poisoning. J Med Chem 2009; 52: 6402-12.
21. da Silva DL, Tavares EC, Conegero LS, de Fatima A, Pilli RA, Fernandes SA. NMR studies of inclusion complexation of the pyrrolizidine alkaloid retronecine and p-sulfonic acid calix[6]arene. J Incl Phenom Macrocycl Chem 2011; 69: 149-55.
22. Paquet V, Zumbuehl A, Carreira EM. Biologically active amphotericin B-calix[4]arene conjugates. Bioconjug Chem 2006; 17: 1460-3.
23. Dibama HM, Clarot I, Fontanay S, et al. Towards calixarene-based prodrugs: Drug release and antibacterial behavior of a watersoluble nalidixic acid/calix[4]arene ester adduct. Bioorg Med Chem Lett 2009; 19: 2679-82.
24. Salem AB, Regnouf-de-Vains JB. Synthesis and characterisation of a new podand based on a calixarene and a β-lactam. Tetrahedron Lett 2001; 42: 7033-6.
25. Motornaya AE, Alimbarova LM, Shokova EA, Kovalev VV. Synthesis and antiherpetic activity of N-(3-amino-1-adamantyl)calix[4]arenes. Pharm Chem J 2006; 40: 68-72.
26. Geller C, Fontanay S, Mourer M, et al. Antiseptic properties of two calix[4]arenes derivatives on the human coronavirus 229E. Antiviral Res 2010; 88: 343-6.
27. Mourer M, Psychogios N, Laumond G, Aubertin AM, Regnouf-de-Vains JB. Synthesis and anti-HIV evaluation of water-soluble calixarene-based bithiazolyl podands. Bioorg Med Chem 2010; 18: 36-45.
28. Kenek K, Kuldová M, Hulíková K, et al. N-Acetyl-D-glucosamine substituted calix[4]arenes as stimulators of NK cell-mediated antitumor immune response. Carbohydr Res 2007; 342: 1781-92.
29. Rouge P, Pires VS, Gaboriau F, et al. Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes. J Enzyme Inhib Med Chem 2010; 25: 216-27.
30. Oliveira MC, Reis FS, de Fátima A, et al. Synthesis and anti-Paracoccidioides activity of calix[n]arenes. Lett Drug Design Discov 2012; 9: 30-6.
31. Vovk AI, Kononets LA, Tanchuk VY, et al. Inhibition of Yersinia protein tyrosine phosphatase by phosphonate derivatives of calixarenes. Bioorg. Med Chem Lett 2010; 20: 483-7.
32. Consoli GML, Granata G, Geraci C. Design, synthesis, and drug solubilising properties of the first folate-calix[4]arene conjugate. Org Biomol Chem 2011; 9: 6491-5.
33. Silva ED, Ficheux D, Coleman AW. Anti-thrombotic activity of water-soluble calix[n]arenes. J Incl Phenom Macrocycl Chem 2005; 52: 201-6.
34. Lugovskoy EV, Gritsenko PG, Koshel TA, et al. Calix[4]arene methylenebisphosphonic acids as inhibitors of fibrin polymerization. FEBS Journal 2011; 278: 1244-51.
35. Shahgaldian P, Silva ED, Coleman AW. A First approach to the study of calixarene solid lipid nanoparticle (SLN) toxicity. J Incl Phenom Macrocycl Chem 2003; 46: 175-7.
36. Coleman AW, Jebors S, Cecillon S, et al. Toxicity and biodistribution of para-sulfonato-calix[4]arene in mice. New J Chem 2008; 32: 780-2.
37. da Silva E, Lazar AN, Coleman AW. Biopharmaceutical applications of calixarenes. J Drug Del Sci Tech 2004; 14: 3-20.
38. Agrawal YK, Bhatt H. Calixarenes and their biomimetic applications. Bioinorg Chem Appl 2004; 2: 237-274.
39. Sidorov V, Kotch FW, Abdrakhmanova G, Mizani R, Fettinger JC, Davis JT. Ion channel formation from a calix[4]arene amide that binds HCl. J Am Chem Soc 2002; 124: 2267-78.
40. Rissanen K. Crystallography and Crystal Engineering. In: Schalley CA, Ed. Analytical Methods in Supramolecular Chemistry, volume 1. 2nd ed. Weinheim: Wiley-VCH 2012; pp. 449-98.
41. Steed JW, Atwood JL. Supramolecular Chemistry. 3rd ed. Chichester: J Wiley & Sons 2009; pp. 441-52.
42. Chiu MH, Prenner EJ. Differential scanning calorimetry: An invaluable tool for a detailed thermodynamic characterization of macromolecules and their interactions. J Pharm Bioall Sci 2011; 3: 39-59.
43. Gill P, Moghadam TT, Ranjbar B. Differential Scanning Calorimetry techniques: applications in biology and nanoscience. J Biomol Techn 2010; 21: 167-93.
44. Yang W, de Villiers MM. Effect of 4-sulphonato-calix[n]arenes and cyclodextrins on the solubilization of niclosamide, a poorly water soluble anthelmintic. AAPS Journal 2005; 7: E241-48.
45. Panchal JG, Patel RV, Menon SK. Preparation and physicochemical characterization of carbamazepine (CBMZ): para-sulfonated calix[n]arene inclusion complexes. J Incl Phenom Macrocycl Chem 2010; 67; 201-8.
46. de Assis JV, Teixeira MG, Soares CGP, et al. Experimental and theoretical NMR determination of isoniazid and sodium psulfonatocalix[n]arenes inclusion complexes. Eur J Pharm Sci 2012; 47, 539-48.
47. Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instrum 1965; 4: 117-212.
48. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007; 59: 645-66.
49. Bayracki M, Ertul A, Yilmaz M. Solubilizing effect of the pphosphonate calix[n]arenes towards poorly soluble drug molecules such as nifedipine, niclosamide and furosemide. J. Incl Phenom Macrocycl Chem 2012; 74: 415-23.
50. Yang W, de Villiers MM. Aqueous solubilization of furosemide by supramolecular complexation with 4-sulphonic calix[n]arenes. J Pharm Pharmacol 2004; 56: 703-8.
51. Yang W, de Villiers MM. The solubilization of the poorly water soluble drug nifedipine by water soluble 4-sulphonic calix[n]arenes. Eur J Pharm Biopharm 2004; 58: 629-36.
52. Wang G-S, Zhang H-Y, Ding F, Liu Y. Preparation and characterization of inclusion complexes of topotecan with sulfonatocalixarene. J Incl Phenom Macrocycl Chem 2011; 69: 85-9.
53. Zadmard R, Ataeian P, Khalili-Foumeshi M. C-Silylated calix[4]arene as a new receptor for aspartate in polar solvents. Org Chem Int 2011; article ID 171374: 5 pages.
54. Fernandes SA, Cabeça LF, Marsaioli AJ, de Paula E. Investigation of tetracaine complexation with beta-cyclodextrins and p-sulphonic acid calix[6]arenes by nOe and PGSE NMR. J Incl Phenom Macrocycl Chem 2007; 57: 395-401.
55. 1H-NMR approaches. Magn Reson Chem 2009; 47: 757-63.
56. Wang X, Luo C, Lv Z, Lu F. Investigation of the inclusion behavior between p-sulfoniccalix[8]arene and norfloxacin by fluorescence spectroscopy. J Lumin 2011; 131: 1986-90.
57. Zhou Y, Ding X, Fang X, Li T, Tang D, Lu Q. Studies on the inclusion behavior of amphiphilic p-sulfonatocalix[4]arene with ascorbic acid by spectrofluorometric titrations. Opt Photonics J 2011; 1: 59-64.
58. a) from Solution NMR Data. Tetrahedron 2000; 56: 6151-70.
59. Cragg PJ. A Practical Guide to Supramolecular Chemistry. Chichester J. Wiley & Sons 2005.
60. Thordarson P. Determining association constants from titration experiments in supramolecular chemistry. Chem Soc Rev 2011; 40: 1305-23.
61. Cameron KS, Fielding L. NMR Diffusion Spectroscopy as a measure of host-guest complex association constants and as a probe of complex size. J Org Chem 2001; 66: 6891-5.
62. Cohen Y, Avram L, Evan-Salem T, Slovak S, Shemesh N, Frish L. Diffusion NMR in Supramolecular Chemistry and Complexed Systems. In: Schalley CA, Ed. Analytical Methods in Supramolecular Chemistry, v. 1. Weinheim: Wiley-VCH 2012; pp. 209-10.
63. Jacobsen NE. NMR spectroscopy explained. Hoboken: J. Wiley & Son 2007.
64. Claridge TDW. High-Resolution NMR Techniques in Organic Chemistry. 2nd ed. Oxford: Elsevier 2009.
65. Mecca T, Cunsolo F. Calix[4]arene-based ligands as endotoxin receptors. Tetrahedron 2007; 63: 10764-7.
66. Iqbal KSJ, Cragg PJ. Transmembrane ion transport by calixarenes and their derivatives. Dalton Trans 2007; 1: 26-32.
67. Tu C, Zhu L, Li P, et al. Supramolecular polymeric micelles by the host-guest interaction of star-like calix[4]arene and chlorin e6 for photodynamic therapy. Chem Commun 2011; 47: 6063-5.
68. Sautrey G, Clarot I, Rogalska E, Regnouf-de-Vains JB. New potential prodrugs of aciclovir using calix[4]arene as a lipophilic carrier: synthesis and drug-release studies at the air-water interface. New J Chem 2012; 36: 2060-9.
69. Wang K, Guo D-S, Wang X, Liu Y. Multistimuli responsive supramolecular vesicles based on the recognition of psulfonatocalixarene and its controllable release of doxorubicin. ACS NANO 2011; 5: 2880-94.
70. Coleman AW, Perret F, Cecillon S, et al. Enhanced detection of the pathogenic prion protein by its supramolecular association with para-sulfonato-calix[n]arene derivatives. New J Chem 2007; 31: 711-17.
71. Dupont N, Lazar AN, Perret F, et al. Solid state structures of the complexes between the antiseptic chlorhexidine and three anionic derivatives of calix[4]arene. Cryst Eng Commun 2008; 10: 975-7.
72. Suwinska K, Coleman AW. Structure of the kanamycincalix[4]arene di-O-phosphonate salt. Cryst Eng Commun 2008; 10: 1302-4.